Why the study?
Does liposome-mediated IL-10 gene transfer improve efficacy and reduce adverse effects compared to adenovirus-mediated transfer in a rabbit heart transplant model?
Does liposome-mediated IL-10 gene transfer improve efficacy and reduce adverse effects compared to adenovirus-mediated transfer in a rabbit heart transplant model?
Liposome-mediated IL-10 gene transfer offers higher efficacy and avoids the significant negative inotropic and arrhythmogenic adverse effects associated with adenovirus vectors in a rabbit heart transplant model.
May favor liposome over adenovirus vectors for IL-10 delivery in transplants; leaves open clinical translation.
Virus- and nonvirus-mediated immunosuppressive cytokine gene therapy prolongs cardiac allograft survival in various nonfunctional heart transplant animal models, but its cardiac adverse effects have not been addressed. Recently, we developed a functional heterotopic heart transplant model in rabbits. For the first time, we were able to systematically compare the efficiency, efficacy, and adverse effects of optimized adenovirus- and liposome-mediated ex vivo interleukin (IL)-10 gene transfer in functional donor hearts. The efficiency of liposome-mediated gene transfer was greatly improved in physiologically functioning donor hearts and was only three- to fourfold lower than adenovirus-mediated gene transfer. The efficacy of liposome-mediated IL-10 gene transfer was much higher than that mediated by adenovirus. Significant negative inotropic and arrhythmogenic adverse effects on transplanted hearts were observed due to viral cytotoxicity and immunogenesis, which greatly abated the therapeutic efficacy of this first generation adenovirus-mediated gene therapy.
No takes yet. Share an insight, caveat, or question.
Sen et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: